Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Metagenomi, Inc. (MGX : NSDQ)

• Company Description    Metagenomi Inc. is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox. Metagenomi Inc. is based in EMERYVILLE, Calif. Number of Employees: 202

• Price / Volume Information    Yesterday's Closing Price: $1.61 Daily Weekly Monthly 20 Day Moving Average: 350,330 shares Shares Outstanding: 37.53 (millions) Market Capitalization: $60.43 (millions) Beta: 0.49 52 Week High: $4.40 52 Week Low: $1.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.29% -7.30% 12 Week -31.20% -32.44% Year To Date -55.40% -61.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5959 HORTON STREET 7TH FLOOR - EMERYVILLE,CA 94608 USA ph: 510-871-4880 fax: - IR@metagenomi.co http://www.metagenomi.co

• General Corporate Information    Officers Brian C. Thomas - Chief Executive Officer and Director Jian Irish, - President; Chief Operating Officer and Director Pamela Wapnick - Chief Financial Officer Sebastian Bernales - Director Eric Bjerkholt - Director Peer Information Metagenomi, Inc. (GSAC) Metagenomi, Inc. (CASI) Metagenomi, Inc. (ALCD.) Metagenomi, Inc. (OMNN) Metagenomi, Inc. (CGPI.) Metagenomi, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 59102M104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 37.53 Most Recent Split Date: (:1) Beta: 0.49 Market Capitalization: $60.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.34 Price/Cash Flow: - Price / Sales: 1.95 EPS Growth vs. Year Ago Period: -22.22% vs. Previous Quarter: -1.85% Sales Growth vs. Year Ago Period: -24.80% vs. Previous Quarter: 1.72% ROE 09/30/25 - -43.19 06/30/25 - -37.84 03/31/25 - -31.21 ROA 09/30/25 - -31.06 06/30/25 - -27.15 03/31/25 - -22.21 Current Ratio 09/30/25 - 6.42 06/30/25 - 6.36 03/31/25 - 5.85 Quick Ratio 09/30/25 - 6.42 06/30/25 - 6.36 03/31/25 - 5.85 Operating Margin 09/30/25 - -287.06 06/30/25 - -251.90 03/31/25 - -167.67 Net Margin 09/30/25 - -287.06 06/30/25 - -257.99 03/31/25 - -172.21 Pre-Tax Margin 09/30/25 - -291.26 06/30/25 - -267.38 03/31/25 - -184.18 Book Value 09/30/25 - 4.75 06/30/25 - 5.24 03/31/25 - 5.69 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©